These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 10658619

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease.
    Mavridis M, Degryse AD, Lategan AJ, Marien MR, Colpaert FC.
    Neuroscience; 1991; 41(2-3):507-23. PubMed ID: 1870701
    [Abstract] [Full Text] [Related]

  • 23. Treatment with a selective MAO B inhibitor prevents loss of dopamine in the nucleus accumbens of MPTP-treated common marmosets.
    Rose S, Nomoto M, Jackson EA, Gibb WR, Jenner P, Marsden CD.
    Neuropharmacology; 1989 Nov; 28(11):1211-6. PubMed ID: 2512516
    [Abstract] [Full Text] [Related]

  • 24. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L, Frohna PA, Joyce JN, Schneider JS.
    Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
    [Abstract] [Full Text] [Related]

  • 25. Peripheral nerve-dopamine neuron co-grafts in MPTP-treated monkeys: augmentation of tyrosine hydroxylase-positive fiber staining and dopamine content in host systems.
    Collier TJ, Elsworth JD, Taylor JR, Sladek JR, Roth RH, Redmond DE.
    Neuroscience; 1994 Aug; 61(4):875-89. PubMed ID: 7838385
    [Abstract] [Full Text] [Related]

  • 26. Transient depletion of nucleus accumbens dopamine content may contribute to initial akinesia induced by MPTP in common marmosets.
    Rose S, Nomoto M, Jenner P, Marsden CD.
    Biochem Pharmacol; 1989 Nov 01; 38(21):3677-81. PubMed ID: 2597167
    [Abstract] [Full Text] [Related]

  • 27. Progression and recovery of Parkinsonism in a chronic progressive MPTP-induction model in the marmoset without persistent molecular and cellular damage.
    Franke SK, van Kesteren RE, Wubben JA, Hofman S, Paliukhovich I, van der Schors RC, van Nierop P, Smit AB, Philippens IH.
    Neuroscience; 2016 Jan 15; 312():247-59. PubMed ID: 26431624
    [Abstract] [Full Text] [Related]

  • 28. Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment.
    Schneider JS, Pope A, Simpson K, Taggart J, Smith MG, DiStefano L.
    Science; 1992 May 08; 256(5058):843-6. PubMed ID: 1350379
    [Abstract] [Full Text] [Related]

  • 29. Spontaneous blink rates correlate with dopamine levels in the caudate nucleus of MPTP-treated monkeys.
    Taylor JR, Elsworth JD, Lawrence MS, Sladek JR, Roth RH, Redmond DE.
    Exp Neurol; 1999 Jul 08; 158(1):214-20. PubMed ID: 10448434
    [Abstract] [Full Text] [Related]

  • 30. Sham surgery does not ameliorate MPTP-induced behavioral deficits in monkeys.
    Taylor JR, Elsworth JD, Sladek JR, Collier TJ, Roth RH, Redmond DE.
    Cell Transplant; 1995 Jul 08; 4(1):13-26. PubMed ID: 7728327
    [Abstract] [Full Text] [Related]

  • 31. Behavioral motor recovery in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned squirrel monkey (Saimiri sciureus): changes in striatal dopamine and expression of tyrosine hydroxylase and dopamine transporter proteins.
    Petzinger GM, Fisher B, Hogg E, Abernathy A, Arevalo P, Nixon K, Jakowec MW.
    J Neurosci Res; 2006 Feb 01; 83(2):332-47. PubMed ID: 16385585
    [Abstract] [Full Text] [Related]

  • 32. A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery.
    Mounayar S, Boulet S, Tandé D, Jan C, Pessiglione M, Hirsch EC, Féger J, Savasta M, François C, Tremblay L.
    Brain; 2007 Nov 01; 130(Pt 11):2898-914. PubMed ID: 17855373
    [Abstract] [Full Text] [Related]

  • 33. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.
    Di Monte DA, McCormack A, Petzinger G, Janson AM, Quik M, Langston WJ.
    Mov Disord; 2000 May 01; 15(3):459-66. PubMed ID: 10830409
    [Abstract] [Full Text] [Related]

  • 34. Fetal nondopaminergic neural implants in parkinsonian primates. Histochemical and behavioral studies.
    Bankiewicz KS, Plunkett RJ, Jacobowitz DM, Kopin IJ, Oldfield EH.
    J Neurosurg; 1991 Jan 01; 74(1):97-104. PubMed ID: 1670609
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Effects of GM1 ganglioside treatment on pre- and postsynaptic dopaminergic markers in the striatum of parkinsonian monkeys.
    Pope-Coleman A, Tinker JP, Schneider JS.
    Synapse; 2000 May 01; 36(2):120-8. PubMed ID: 10767059
    [Abstract] [Full Text] [Related]

  • 37. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism.
    Graham WC, Sambrook MA, Crossman AR.
    Brain Res; 1993 Feb 05; 602(2):290-303. PubMed ID: 8095431
    [Abstract] [Full Text] [Related]

  • 38. Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP.
    Rose S, Nomoto M, Kelly E, Kilpatrick G, Jenner P, Marsden CD.
    Neurosci Lett; 1989 Jul 03; 101(3):305-10. PubMed ID: 2505199
    [Abstract] [Full Text] [Related]

  • 39. Chronic CY 208-243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors.
    Gagnon C, Gomez-Mancilla B, Bédard PJ, Di Paolo T.
    Neurosci Lett; 1993 Nov 26; 163(1):31-5. PubMed ID: 7905197
    [Abstract] [Full Text] [Related]

  • 40. Neurochemical evaluation of the striatum in symptomatic and recovered MPTP-treated cats.
    Schneider JS, Rothblat DS.
    Neuroscience; 1991 Nov 26; 44(2):421-9. PubMed ID: 1944893
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.